{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:39:40Z","timestamp":1792708780544,"version":"4.5.0"},"reference-count":54,"publisher":"The Korean Society of Anesthesiologists","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["anesth-pain-med.org"],"crossmark-restriction":true},"short-container-title":["Anesth Pain Med"],"published-print":{"date-parts":[[2022,1,31]]},"abstract":"<jats:p>A novel ultra-short-acting benzodiazepine (BDZ), remimazolam (CNS 7056), has been designed by \u2018soft drug\u2019 development to achieve a better sedative profile than that of the current drugs. Notably, the esterase linkage in remimazolam permits rapid hydrolysis to inactivate metabolites by non-specific tissue esterase and induces a unique and favorable pharmacological profile, including rapid onset and offset of sedation and a predictable duration of action. Similar to other BDZs, its sedative effects can be reversed using flumazenil, a BDZ antagonist. The pharmacokinetics and pharmacodynamics of remimazolam are characterized by relatively high clearance, small steady-state volume of distribution, short elimination half-life, short context-sensitive half-life, and fast onset and recovery, indicating rapid elimination, minimal tissue accumulation, and good control. In addition, remimazolam possesses a superior safety profile, including low liability for cardiorespiratory depression and injection pain, making it a preferred hypnotic agent in various clinical settings. Early clinical investigations suggest that remimazolam is well tolerated and effective for procedural sedation and for induction and maintenance of general anesthesia. To date, however, the clinical use of remimazolam has been confined to a few volunteer studies and a limited number of clinical investigations. Therefore, further studies regarding its recovery issues or postoperative complications, characteristics of electroencephalogram changes, and cost-benefit analyses are required to facilitate its widespread use.<\/jats:p>","DOI":"10.17085\/apm.21115","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T19:09:34Z","timestamp":1642619374000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.17085\/crossmark_policy","source":"Crossref","is-referenced-by-count":246,"title":["Remimazolam: pharmacological characteristics and clinical applications in anesthesiology"],"prefix":"10.17085","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6893-1539","authenticated-orcid":true,"given":"Kyung Mi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2573","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.690875"},{"key":"ref2","first-page":"256","volume-title":"The benzodiazepine binding site of GABA<sub>A<\/sub> receptors. Trends Pharmacol Sci 1997; 18: 425-9","author":"Sigel","year":"1998"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/1658-354x.136627"},{"key":"ref4","first-page":"229","volume-title":"Is anesthesiology going soft?: trends in fragile pharmacology","author":"Egan","year":"2009"},{"key":"ref5","first-page":"60","volume-title":"CNS 7056: a novel ultra-short-acting Benzodiazepine","author":"Kilpatrick","year":"2007"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e3182a705ae"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01544-8"},{"key":"ref8","first-page":"274","volume-title":"A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics","author":"Antonik","year":"2012"},{"key":"ref9","first-page":"251","volume-title":"Population pharmacokinetic\/pharmacodynamic model-guided dosing optimization of a novel sedative HR7056 in Chinese healthy subjects. Front Pharmacol 2018; 9: 1316","author":"Zhou","year":"2019"},{"key":"ref10","first-page":"636","volume-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics","author":"Sch\u00fcttler","year":"2020"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02800-3"},{"key":"ref12","first-page":"217","volume-title":"Remimazolam: new beginnings or just a me-too?","author":"Sneyd","year":"2012"},{"key":"ref13","first-page":"1033","volume-title":"Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system","author":"Freyer","year":"2019"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.01.016"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02755-1"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1806"},{"key":"ref17","first-page":"284","volume-title":"A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation","author":"Wiltshire","year":"2012"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2199\/jjsca.34.860"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2021.05.027"},{"key":"ref20","first-page":"929","volume-title":"Remimazolam, a short-acting GABAA receptor agonist for intravenous sedation and\/or anesthesia in day-case surgical and non-surgical procedures","author":"Rogers","year":"2010"},{"key":"ref21","first-page":"244","volume-title":"Validity and reliability of the Observer's Assessment of Alertness\/Sedation Scale: study with intravenous midazolam","author":"Chernik","year":"1990"},{"key":"ref22","first-page":"652","volume-title":"Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of electroencephalogram effects","author":"Eisenried","year":"2020"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1552"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/anae.13316"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-010-0907-4"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200111000-00019"},{"key":"ref27","first-page":"70","volume-title":"Target-controlled infusion: a mature technology","author":"Absalom","year":"2016"},{"key":"ref28","first-page":"300; author reply 300","volume-title":"Remifentanil manual versus target-controlled infusion","author":"Sneyd","year":"2003"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/aco.0000000000000877"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2020.109899"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/eja.0000000000000683"},{"key":"ref32","first-page":"4594","volume-title":"The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial","author":"Chen","year":"2020"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2018.04.2351"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15188"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2334\/josnusd.21-0051"},{"key":"ref36","first-page":"173","volume-title":"Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial. BMC Anesthesiol 2021; 21: 156","author":"Zhang","year":"2021"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2012.11.039"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.10.039"},{"key":"ref39","volume-title":"","year":"2018"},{"key":"ref40","volume-title":""},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02788-6"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02776-w"},{"key":"ref43","volume-title":""},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-020-02864-x"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002401013"},{"key":"ref46","first-page":"442","volume-title":"Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs 1991; 42: 1061-89","author":"Brogden","year":"1992"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814010-00001"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12731"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-021-02915-x"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-021-02930-y"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14270"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.1901575"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1614"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2020.11.021"}],"container-title":["Anesthesia and Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/anesth-pain-med.org\/upload\/pdf\/apm-21115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/anesth-pain-med.org\/journal\/view.php?doi=10.17085\/apm.21115","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/anesth-pain-med.org\/upload\/pdf\/apm-21115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T01:53:52Z","timestamp":1643248432000},"score":1,"resource":{"primary":{"URL":"http:\/\/anesth-pain-med.org\/journal\/view.php?doi=10.17085\/apm.21115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.17085\/apm.21115","relation":{},"ISSN":["1975-5171","2383-7977"],"issn-type":[{"value":"1975-5171","type":"print"},{"value":"2383-7977","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"2021-12-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}